Skip to main content

Advertisement

SpringerLink
Log in

Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Polymorphism in 5,10-methylenetetrahydrofolate reductase (MTHFR), a central enzyme in folate metabolism, has been shown to affect the sensitivity of patients to folate-based drugs such as methotrexate. In this study, we investigated whether a common single nucleotide polymorphism at position 677 in the donor or recipient’s MTHFR gene affects the risk for acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling donors when the recipient receives prophylactic treatment with methotrexate for GVHD. MTHFR genotypes were determined in 159 recipients with a hematological disease and their donors using polymerase chain reaction–restriction fragment length polymorphism analysis of genomic DNA. The 677TT genotype, which encodes an enzyme with approximately 30% of the activity of the wild-type (677CC), was observed in 13% of patients and in 8% of normal donors. Multivariate analyses demonstrated a significant association between 677TT genotype in patients and a lower incidence of grade I–IV acute GVHD (relative risk, 0.35; 95% confidence interval, 0.13–0.95; P = 0.040). There was no association between the incidence of acute GVHD and the donor MTHFR genotypes. These results suggest that greater immunosuppression by methotrexate due to low MTHFR enzyme activity decreases the risk of acute GVHD in recipients of allogeneic HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Imamura M, Asano S, Harada M, et al. Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. Int J Hematol. 2006;83:164–78.

    Article  PubMed  Google Scholar 

  2. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;36:757–69.

    Article  CAS  PubMed  Google Scholar 

  3. Petersdorf EW. Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol. 2006;18:559–64.

    Article  CAS  PubMed  Google Scholar 

  4. Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? Bone Marrow Transplant. 2005;35:1–16.

    Article  CAS  PubMed  Google Scholar 

  5. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E, et al. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol. 2004;127:479–90.

    Article  CAS  PubMed  Google Scholar 

  6. Mullighan CG, Bardy PG. New directions in the genomics of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:127–44.

    Article  CAS  PubMed  Google Scholar 

  7. Riddell SR, Murata M, Bryant S, Warren EH. Minor histocompatibility antigens-targets of graft versus leukemia responses. Int J Hematol. 2002;76(Suppl 2):155–61.

    Article  PubMed  Google Scholar 

  8. Terakura S, Murata M, Nishida T, et al. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant. 2006;37:381–6.

    Article  CAS  PubMed  Google Scholar 

  9. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003;197:1279–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Terakura S, Murata M, Nishida T, et al. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol. 2005;129:221–8.

    Article  CAS  PubMed  Google Scholar 

  11. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003;3:912–20.

    Article  CAS  PubMed  Google Scholar 

  12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.

    Article  CAS  PubMed  Google Scholar 

  13. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–35.

    Article  CAS  PubMed  Google Scholar 

  14. Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol. 1999;26(2 Suppl 6):3–10.

    CAS  PubMed  Google Scholar 

  15. Robien K, Bigler J, Yasui Y, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2006;12:973–80.

    Article  CAS  PubMed  Google Scholar 

  16. Murphy N, Diviney M, Szer J, et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant. 2006;37:773–9.

    Article  CAS  PubMed  Google Scholar 

  17. Pihusch M, Lohse P, Reitberger J, et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78:911–8.

    Article  CAS  PubMed  Google Scholar 

  18. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–76.

    CAS  PubMed  Google Scholar 

  19. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  PubMed  Google Scholar 

  20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.

    Article  PubMed  Google Scholar 

  21. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187–220.

    Google Scholar 

  22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457–81.

    Article  Google Scholar 

  23. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151:862–77.

    Article  CAS  PubMed  Google Scholar 

  24. Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS, Franco RF. 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1956–63.

    Article  CAS  PubMed  Google Scholar 

  25. Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252–6.

    CAS  PubMed  Google Scholar 

  26. Kalayoglu-Besisik S, Caliskan Y, Sargin D, Gurses N, Ozbek U. Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation. 2003;76:1775–7.

    Article  PubMed  Google Scholar 

  27. Kimura M, Umegaki K, Higuchi M, Thomas P, Fenech M. Methylenetetrahydrofolate reductase C677T polymorphism, folic acid and riboflavin are important determinants of genome stability in cultured human lymphocytes. J Nutr. 2004;134:48–56.

    Article  CAS  PubMed  Google Scholar 

  28. Hryniuk WM. Purineless death as a link between growth rate and cytotoxicity by methotrexate. Cancer Res. 1972;32:1506–11.

    CAS  PubMed  Google Scholar 

  29. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13:1915–8.

    Article  CAS  PubMed  Google Scholar 

  30. Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res. 2007;31:1669–74.

    Article  CAS  PubMed  Google Scholar 

  31. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C–>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer. 2003;103:294–9.

    Article  CAS  PubMed  Google Scholar 

  32. Toffoli G, Veronesi A, Boiocchi M, Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol. 2000;11:373–4.

    Article  CAS  PubMed  Google Scholar 

  33. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231–4.

    Article  CAS  PubMed  Google Scholar 

  34. Robien K, Schubert MM, Chay T, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:799–800.

    Article  CAS  PubMed  Google Scholar 

  35. Kim I, Lee KH, Kim JH, et al. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2007;86:41–8.

    Article  CAS  PubMed  Google Scholar 

  36. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer. 1992;69:2469–77.

    Article  CAS  PubMed  Google Scholar 

  37. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004;96:134–44.

    Article  CAS  PubMed  Google Scholar 

  38. Matsuo K, Suzuki R, Morishima Y, Hamajima N. Attribution of posttransplantation toxicity to methotrexate regarding genotype of methylenetetrahydrofolate reductase gene (MTHFR) polymorphism needs further clarification. Blood. 2001;98:2283.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the Ministry of Health and Welfare of Japan (to MM and YK).

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan

    Kyoko Sugimoto, Makoto Murata, Seitaro Terakura & Tomoki Naoe

  2. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

    Makoto Onizuka, Yoshihiro Inamoto, Yachiyo Kuwatsuka, Taku Oba, Koichi Miyamura & Yoshihisa Kodera

  3. Department of Hematology and Rheumatology, Tokai University School of Medicine, Bouseidai, Japan

    Makoto Onizuka

Authors
  1. Kyoko Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makoto Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Onizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshihiro Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seitaro Terakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yachiyo Kuwatsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Taku Oba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koichi Miyamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshihisa Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tomoki Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Murata.

About this article

Cite this article

Sugimoto, K., Murata, M., Onizuka, M. et al. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol 87, 451–458 (2008). https://doi.org/10.1007/s12185-008-0061-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0061-z

Keywords

Search

Navigation